Adult Neurogenesis Therapeutics Investment Landscape

Adult Neurogenesis Therapeutics for Neurodegeneration

Latest Data Snapshot (March 2026)

> Data refreshed: 2026-03-14 PT from ClinicalTrials.gov

| Metric | Value |
|---|---:|
| Total Clinical Trials | 34 |
| Active Trials (Recruiting/Active) | 9 (26%) |
| Phase 1 Trials | 7 |
| Phase 2 Trials | 2 |
| Phase 3 Trials | 0 |

Overview

Adult Neurogenesis Therapeutics for Neurodegeneration

Latest Data Snapshot (March 2026)

> Data refreshed: 2026-03-14 PT from ClinicalTrials.gov

| Metric | Value |
|---|---:|
| Total Clinical Trials | 34 |
| Active Trials (Recruiting/Active) | 9 (26%) |
| Phase 1 Trials | 7 |
| Phase 2 Trials | 2 |
| Phase 3 Trials | 0 |

Overview

Adult Neurogenesis Therapeutics represents an emerging investment area focused on stimulating the brain's natural ability to generate new [neurons](/entities/neurons) to treat neurodegenerative diseases. This investment landscape analyzes funding trends, key companies, clinical trials, and opportunities in this field. [@adult2023]

Adult neurogenesis - the production of new neurons in the adult brain - occurs primarily in two regions: the subventricular zone (SVZ) lining the ventricles and the subgranular zone (SGZ) of the dentate gyrus in the [hippocampus](/brain-regions/hippocampus). This capacity diminishes with age and is impaired in neurodegenerative diseases, making restoration of neurogenesis a compelling therapeutic approach.

Biological Rationale

Why Neurogenesis Matters

Challenges

• Survival: Most new neurons die within weeks of birth
• Integration: Functional circuit integration is challenging
• Delivery: Getting cells or drugs to appropriate brain regions
• Timing: When in disease progression is intervention most effective?

Investment Trends

Funding Overview

The adult neurogenesis therapeutics field has attracted increasing investment interest from venture capital and pharmaceutical companies: [@neurogenesis2024]

• Venture Capital: Active investment in stem cell therapy companies and neural regeneration startups
• Pharma Partnerships: Major pharmaceutical companies partnering with academic labs and biotech
• Government Funding: NIH and EU grants supporting neural stem cell research

Market Size

• Growing from $500M (2020) to projected $2B+ by 2030
• Primary indications: Alzheimer's disease, Parkinson's disease, stroke recovery

Key Companies and Programs

Clinical-Stage Companies

| Company | Program | Phase | Mechanism |
|---------|---------|-------|-----------|
| Neuralstem | NSI-189 | Phase 2 | Neural stem cell therapy |
| Lundbeck | Lu AF20513 | Phase 1 | Immunotherapy targeting [Aβ](/proteins/amyloid-beta) |
| Cyto Therapeutics | — | Preclinical | Neural stem cell encapsulation |

Research-Stage Companies

• StemoniX: iPSC-derived neural cells for drug screening
• Neuron梯: Neural stem cell therapy for PD
• Aspen Neuroscience: Autologous neuron replacement

Pipeline Analysis

Stem Cell Approaches

Small Molecule Approaches

• NSI-189: Phenylpyridine analog promoting neurogenesis
• Antidepressants: SSRIs shown to enhance neurogenesis
• Exercise mimetics: BDNF-boosting compounds

Gene Therapy

• BDNF delivery: Neurotrophic factor expression
• Notch pathway modulation: Stem cell fate programming

Gap Analysis

Underrepresented Areas

Investment Opportunities

• Autologous iPSC-derived neuron therapy
• Small molecule neurogenesis enhancers
• Biomarker development for patient selection
• Brain-penetrant neurotrophic factors

Conclusion

Adult neurogenesis therapeutics represent a long-term bet on neural regeneration. While no late-stage programs exist yet, the fundamental biology provides a compelling rationale. Key to success will be:

• Demonstrating functional integration of new neurons
• Safe and scalable cell manufacturing
• Optimal patient selection

Cross-Links

• [Neural Stem Cells](/cell-types/neural-stem-cells)
• [Hippocampus](/brain-regions/hippocampus)
• [Subventricular Zone](/anatomy/subventricular-zone)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [BDNF](/proteins/bdnf-protein)

See Also

• [Novel Therapy Index](/ideas/novel-therapy-index)
• [Investment Landscape: Stem Cell Therapy](/content/investment)
• [Investment Landscape: Neurotrophic Factors](/content/investment)

See Also

• [Adult Neurogenesis](/content/genes)
• [Neurogenesis Therapeutics](/content/therapeutics)

External Links

• [Neurogenesis Review](https://www.nature.com/articles/s41582-019-0264-3)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
• [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;